GOOD PRACTICE IN THE POSTMARKETING SURVEILLANCE OF MEDICINES

Authors
MEYBOOM RHB
Citation
Rhb. Meyboom, GOOD PRACTICE IN THE POSTMARKETING SURVEILLANCE OF MEDICINES, Pharmacy world & science, 19(4), 1997, pp. 186-190
Citations number
43
Categorie Soggetti
Pharmacology & Pharmacy",Chemistry
Journal title
Pharmacy world & science → ACNP
ISSN journal
09281231
Volume
19
Issue
4
Year of publication
1997
Pages
186 - 190
Database
ISI
SICI code
0928-1231(1997)19:4<186:GPITPS>2.0.ZU;2-V
Abstract
in addition to Good Clinical Trial Practice for the study of experimen tal drugs, regulations are also needed for good practice in the assess ment of medicines after approval (Good PM Practice, GPP). GPP has to p rotect the Interests of public health at large as well as those of ind ividual patients, investigators and pharmaceutical companies. GPP may be natural way to solve threatening conflicts between privacy legislat ion and the public interest.